-
-
-
-
-
-
-
Carlisle (CSL) PT Lowered to $370 at Loop Capital
-
-
-
-
-
-
-
Travere Therapeutics (TVTX) and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy
-
-
-
-
-
-
-
Truist Securities Starts Carlisle (CSL) at Hold
-
-
-
-
-
-
-
Carlisle (CSL) PT Raised to $506 at Baird
-
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

